Cargando…

Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics

ONS-3010 is being developed by Oncobiologics Inc. (Cranbury, NJ, USA) as a biosimilar of Humira(®). This randomized, double blind, single-center phase I study (EudraCT registration # 2013-003551-38) was performed to demonstrate pharmacokinetic (PK) biosimilarity between two reference products (Humir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dillingh, Marlous R., Reijers, Joannes A. A., Malone, Karen E., Burggraaf, Jacobus, Bahrt, Kenneth, Yamashita, Liz, Rehrig, Claudia, Moerland, Matthijs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124695/ https://www.ncbi.nlm.nih.gov/pubmed/27965661 http://dx.doi.org/10.3389/fimmu.2016.00508

Ejemplares similares

Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

Adverse immunostimulation caused by impurities: The dark side of biopharmaceuticals
por: Reijers, Joannes A. A., et al.
Publicado: (2019)

Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals
por: Reijers, Joannes A. A., et al.
Publicado: (2017)

Trastuzumab Induces an Immediate, Transient Volume Increase in Humans: A Randomised Placebo-Controlled Trial
por: Reijers, Joannes A.A., et al.
Publicado: (2015)

Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies
por: Reijers, Joannes A. A., et al.
Publicado: (2016)

Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®
por: Magnenat, Laurent, et al.
Publicado: (2016)

Quality by Design–Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®
por: Zhang, Erhui, et al.
Publicado: (2020)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
por: Kwon, Joon-Cheol, et al.
Publicado: (2021)

Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects
por: Hyland, Elizabeth, et al.
Publicado: (2016)

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects
por: Hillson, Jan, et al.
Publicado: (2018)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
por: Zhang, Hong, et al.
Publicado: (2021)

MDCO-216 Does Not Induce Adverse Immunostimulation, in Contrast to Its Predecessor ETC-216
por: Reijers, Joannes A. A., et al.
Publicado: (2017)

Confirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim
por: Desai, Kalpna, et al.
Publicado: (2016)

Comparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
por: Choi, Chungam, et al.
Publicado: (2018)

Genomic variation in 3,010 diverse accessions of Asian cultivated rice
por: Wang, Wensheng, et al.
Publicado: (2018)

Turn-ons for axons
por: Dove, Alan W.
Publicado: (2002)

Adalimumab (Humira™) in Ophthalmology: A Review of the Literature
por: Neri, Piergiorgio, et al.
Publicado: (2010)

Adalimumab (Humira) induced acute lung injury
por: Kohli, Ritesh, et al.
Publicado: (2013)

A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease
por: Kallend, D.G., et al.
Publicado: (2016)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations
por: Kaneko, Kayoko, et al.
Publicado: (2022)

Omiganan Enhances Imiquimod‐Induced Inflammatory Responses in Skin of Healthy Volunteers
por: Niemeyer‐van der Kolk, Tessa, et al.
Publicado: (2020)

IniciaciÓn al ajedrez /
por: Ponce Sala, Lorenzo
Publicado: (1998)

Put-Offs and Come-Ons
por: Dominian, J.
Publicado: (1968)

Breast Cancer Status in Iran: Statistical Analysis of 3010 Cases between 1998 and 2014
por: Akbari, Mohammad Esmaeil, et al.
Publicado: (2017)

Immune Monitoring of Mycophenolate Mofetil Activity in Healthy Volunteers Using Ex Vivo T Cell Function Assays
por: in ’t Veld, Aliede E., et al.
Publicado: (2023)

Whole blood assay as a model for in vitro evaluation of inflammasome activation and subsequent caspase-mediated interleukin-1 beta release
por: Tran, Thi Anh Thu, et al.
Publicado: (2019)

Immunomonitoring of Tacrolimus in Healthy Volunteers: The First Step from PK- to PD-Based Therapeutic Drug Monitoring?
por: in ‘t Veld, Aliede E., et al.
Publicado: (2019)

Wat ons vak nodig heeft
por: Hamel, Margot
Publicado: (2020)

Trots op ons nieuwe tijdschrift
por: van Atten, Ellis
Publicado: (2020)

Optimal use of oral nutritional supplements (ONS) in medical nutrition therapy: ONS consensus report from KEPAN
por: Bahat, Gulistan, et al.
Publicado: (2022)

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
por: Tebbey, Paul W, et al.
Publicado: (2015)

Monitoring of Ex Vivo Cyclosporin a Activity in Healthy Volunteers Using T Cell Function Assays in Relation to Whole Blood and Cellular Pharmacokinetics
por: in ’t Veld, Aliede E., et al.
Publicado: (2022)

Novel SGLT2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected renal effects
por: van Meer, Leonie, et al.
Publicado: (2017)

Pharmacodynamic Biomarkers Evidentiary Considerations for Biosimilar Development and Approval
por: Strauss, David G., et al.
Publicado: (2022)

Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds
por: Radanovic, Igor, et al.
Publicado: (2022)

A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers
por: Makarenko, Igor, et al.
Publicado: (2023)

Add-ons in IVF programme – Hype or Hope?
por: Datta, AK, et al.
Publicado: (2015)

Wat staat ons te wachtenin 2022?
por: Berends, Nienke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_un3l5dms4oeo0jdo8dbrdoju46